Q32 Bio Inc Reaches 20-Day High on Akebia Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 01 Dec 25
Q32 Bio Inc. Common Stock is up 85.39% in pre-market trading, reaching a 20-day high. This surge follows Akebia's acquisition of Q32 Bio's next-generation kidney disease treatment for $7 million.
The acquisition is expected to enhance Akebia's competitive position in the renal market, with plans to initiate a Phase 2 clinical trial for the drug in 2026. This strategic move aligns with Akebia's goal to develop a robust kidney disease drug pipeline.
The positive market reaction reflects investor confidence in the potential of the acquired treatment to address rare kidney diseases, which could significantly improve patient outcomes and drive long-term growth for Akebia.
Analyst Views on QTTB
Wall Street analysts forecast QTTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTTB is 15.00 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.950
Low
10.00
Averages
15.00
High
20.00
Current: 3.950
Low
10.00
Averages
15.00
High
20.00
About QTTB
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
